Evidence map›Paper›PMID 39096090›Full record

ArticleCancer medicine2024

Survival improvements in esophageal and gastric cancers in the Nordic countries favor younger patients.

Kari Hemminki, Frantisek Zitricky, Asta Försti, Otto Hemminki, Vaclav Liska, Akseli Hemminki

Abstract read
In one paragraph

Article in Cancer medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Kari HemminkiBiomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.ORCID 0000-0002-2769-3316
Frantisek ZitrickyBiomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.ORCID 0000-0001-7600-7143
Asta FörstiHopp Children's Cancer Center (KiTZ), Heidelberg, Germany.
Otto HemminkiDepartment of Urology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Vaclav LiskaBiomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
Akseli HemminkiCancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.ORCID 0000-0001-7103-8530

Funding

Finnish Cancer OrganizationsHorizon 2020 Framework Programme 856620Jane ja Aatos Erkon SäätiöNational Institute for Cancer Research - NICR, Programme EXCELES, LX22NPO5102Novo Nordisk FondenPäivikki ja Sakari Sohlbergin SäätiöSigrid Juselius FoundationThe Cooperatio Program, research area SURGUniversity of Helsinki, Helsinki University Central Hospital
6 · The paper itself

Abstract

Esophageal cancer (EC) and gastric cancer (GC) are fatal cancers with a relatively late age of onset. Age is a negative risk factor for survival in many cancers and our aim was to analyze age-specific survival in EC and GC using the recently updated NORDCAN database. NORDCAN data originate from the Danish, Finnish, Norwegian, and Swedish nationwide cancer registries covering years 1972 through 2021 inviting for comparison of 50-year survival trends between the countries. Relative 1- and 5-year survival and 5/1-year conditional survival (i.e., survival in those who were alive in Year 1 to survive additional 4 years) were analyzed. Survival in EC showed large gains for patients below age 80 years, 5-year survival in Norwegian men reaching 30% and in women over 30% but for 80-89 year old survival remained at 10%. In contrast, hardly any gain was seen among the 80-89 year patients for 1-year survival and small gains in 5 year and 5/1-year survival. Survival gaps between age-groups increased over time. For GC there was also a clear age-related negative survival gradient but the survival gaps between the age groups did not widen over time; Norwegian male and female 5-year survival for 80-89 year old was about 20%. The age-specific survival difference in GC arose in Year 1 and did not essentially increase in 5-year survival. While there were differences in survival improvements between the countries, poor survival of the 80-89 year old patients was shared by all of them. To conclude, survival has improved steadily in younger GC and EC patients in most Nordic countries. While the 80-89 year old population accounts for nearly a quarter of all patients and their poor survival depressed overall survival, which can therefore be increased further by improving diagnostics, treatment and care of elderly EC and GC patients.

Indexed as

Esophageal NeoplasmsRegistriesStomach NeoplasmsAdultAgedAged, 80 and overAge FactorsFemaleHumansMaleMiddle AgedScandinavian and Nordic CountriesSurvival Ratemortalityrelative survivalrisk factorsstomach cancertreatment

Identifiers

PMID39096090
PMCPMC11297530

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.